IM Cannabis has completed the sale of its IMC Holdings subsidiary to a related party, retaining its Israeli operations. This transaction is expected to improve the company's shareholders' equity and working capital by approximately C$3 million, reduce liabilities, and streamline its corporate structure, allowing it to focus on its core Israeli medical cannabis business.
IM Cannabis (IMCC) has divested its IMC Holdings subsidiary, which included interests in Adjupharm GmbH, Xinteza API Ltd., and Shiran Societe Anonyme, to Slil, a company controlled by IMCC's CEO. Prior to the sale, IMCC transferred its Israeli operations out of IMC Holdings, effectively retaining its core business. This move is significant as it's projected to improve IMCC's shareholders' equity by C$3 million and reduce consolidated liabilities, addressing the company's 'serious financial difficulty' as cited for MI 61-101 exemptions. For traders, this could be a short-term positive catalyst as it signals a cleaner balance sheet and a focused strategy on the Israeli medical cannabis market. The long-term implication depends on the success of the retained Israeli operations and how effectively the company leverages its streamlined structure. The key opportunity is the potential for a more financially stable and focused IMCC, while a risk could be the reliance on a related-party transaction and the actual financial impact differing from the estimate.